Results 201 to 210 of about 186,761 (273)

Hyperprogression after Anti-Programmed Death-1 Therapy in a Case of Sigmoid Colon Cancer with Lynch Syndrome. [PDF]

Surg Case Rep
Miura R, Ohira G, Maruyama M, Tochigi T, Maruyama T, Okada K, Hirata A, Matsubara H.   +7 more
europepmc   +1 more source

Molecular and Cell Biological Characterization of Patient‐Derived Head and Neck Squamous Carcinoma Cell Lines

Cancer Science, EarlyView.
Patient‐derived head and neck squamous cell carcinoma (HNSCC) cells were genomically and cytogenetically characterized, revealing actionable alterations and chromosomal instability. Targeted therapies suppressed growth according to EGFR amplification or PIK3CA mutation status.
Kazue Ito, Noriko Ishida, Shin Ito, Norihisa Shindo, Satoshi Souma, Mai Mochizuki, Haruna Fujimori, Keiichi Tamai, Takayuki Imai, Tomoko Yamazaki, Kazunori Yamaguchi, Kento Sasaki, Yuya Miyakura, Shigekazu Murakami, Yuka Unno, Naoki Asano, Yukinori Asada, Jun Yasuda   +17 more
wiley   +1 more source

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. [PDF]

Clin Cancer Res
Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, de Claro RA, Pazdur R, Lemery SJ.   +8 more
europepmc   +1 more source

When Binding Is Not Blockade: Interpreting IgG4+ T Cells After PD‐1 Therapy

Cancer Science, EarlyView.
IgG4 positivity on circulating T cells after PD‐1 therapy may indicate residual antibody binding rather than sustained functional PD‐1 blockade. During sequential ramucirumab plus docetaxel plus G‐CSF treatment, peripheral IgG4+ T‐cell dynamics may also be influenced by redistribution and treatment‐related confounders, limiting direct inference about ...
Man Sun, Dan Zang, Jun Chen
wiley   +1 more source

Pembrolizumab-Responsive Cerebellar PML in Untreated Sarcoidosis: A Case Report. [PDF]

Cerebellum
Jack-Kee E, Hoyle N, Hadjivassiliou M.
europepmc   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

BJU International, EarlyView.
Kevin G. Keane, Richard Gauci, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Andrisha‐Jade Inderjeeth, Ian D. Davis, Jayne Lim, Andrew Redfern, Dickon Hayne   +9 more
wiley   +1 more source

Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis. [PDF]

BMC Health Serv Res
Rui M, Wei Q, Wang Y, You JHS.
europepmc   +1 more source

Real‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to
Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer   +11 more
wiley   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source